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Abstract
Lower adherence to antihypertensive medications may increase visit-to-visit variability of blood 
pressure (VVV of BP), a risk factor for cardiovascular events and death. We used data from the 
African American Study of Kidney Disease and Hypertension (AASK) Trial to examine whether 
lower medication adherence is associated with higher systolic VVV of BP in African Americans 
with hypertensive CKD. Determinants of VVV of BP were also explored. AASK participants 
(n=988) were categorized by self-report or pill count as having perfect (100%), moderately high 
(75–99%), moderately low (50–74%), or low (<50%) proportion of study visits with high 
medication adherence over a one year follow-up period. We used multinomial logistic regression 
to examine determinants of medication adherence, and multivariable-adjusted linear regression to 
examine the association between medication adherence and systolic VVV of BP, defined as the 
coefficient of variation or the average real variability. Participants with lower self-reported 
adherence were generally younger and had a higher prevalence of comorbid conditions. Compared 
with perfect adherence, moderately high, moderately low, and low adherence was associated with 
0.65% (±0.31%), 0.99% (±0.31%) and 1.29% (±0.32%) higher systolic VVV of BP (defined as the 
coefficient of variation) in fully adjusted models. Results were qualitatively similar when using 
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average real variability or when using pill counts as the measure of adherence. Lower medication 
adherence is associated with higher systolic VVV of BP in African Americans with hypertensive 
CKD; efforts to improve medication adherence in this population may reduce systolic VVV of BP.
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INTRODUCTION
Blood pressure fluctuates from day to day—a phenomenon known as visit-to-visit variability 
of blood pressure (VVV of BP)(ref. 1). VVV of BP is emerging as an important independent 
risk factor for cardiovascular events and death (ref. 2,3,4,5,6,7), although there is still no 
consensus on what constitutes “high” versus “normal” VVV of BP. Lower medication 
adherence has been postulated as a determinant of higher VVV of BP, but few studies have 
systematically tested this hypothesis. One recent study found that lower medication 
adherence was associated with higher VVV of BP, but only explained a small proportion of 
overall VVV of BP(ref. 8). However, that study was limited by the fact that blood pressure 
was not measured according to a standardized protocol, and had only one blood pressure 
measurement per visit in most cases.
African Americans have a higher prevalence of hypertension than other racial groups, lower 
medication adherence rates, and are more likely to develop cardiovascular disease compared 
to whites (ref. 9,10,11,12). Additionally, chronic kidney disease (CKD) is associated with 
more severe hypertension and higher VVV of BP (ref. 13,14,15,16). Understanding the 
association between medication adherence (a potentially modifiable risk factor) and VVV of 
BP in African Americans with CKD may provide additional impetus for improving 
medication adherence in this high-risk population. Therefore, we conducted a secondary 
analysis of the African American Study of Kidney Disease and Hypertension (AASK) Trial 
to examine correlates of lower antihypertensive medication adherence and whether it is 
associated with higher VVV of BP in African Americans with hypertensive CKD.
PARTICIPANTS AND METHODS
Cohort Assembly
Details of the AASK Trial have been previously reported(ref. 17). AASK was a multicenter 
clinical trial that enrolled 1094 African American participants aged 18 to 70 years with 
hypertensive kidney disease (measured glomerular filtration rate [GFR] 20–65 mL/min per 
1.73m2) from February 1995 to September 1998. Participants were randomized in a 3×2 
factorial design to receive one of three antihypertensive medications (ramipril, metoprolol or 
amlodipine) and to one of two BP targets (mean arterial pressure ≤92 mm Hg or 102–107 
mm Hg). Exclusion criteria included a history of diabetes mellitus, diastolic BP <95 mm Hg, 
and urinary protein to creatinine ratio >2.5 g/g.
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Systolic Visit-to-Visit Variability of Blood Pressure
For the current study, we calculated systolic VVV of BP based on systolic BP recorded 
during the first year of follow-up after randomization. Participants who reached end-stage 
renal disease or who died within the first 12 months were excluded from the analysis. 
Participants had study visits monthly for the first 6 months following randomization and 
every other month for the remainder of the study. However, participants could be seen more 
frequently to guide antihypertensive treatment. At each study visit, BP was measured in 
triplicate with participants in the seated position after at least 5 minutes of rest using a 
random zero sphygmomanometer; the mean of the last two measurements was used to define 
BP at the study visit. For this analysis, we excluded BP measured during the first two 
months as there were frequent medication titrations during this period. Participants were 
only included if they had BP measurements from at least 6 follow-up visits. For each 
participant, we calculated systolic VVV of BP using the coefficient of variation (standard 
deviation divided by mean systolic BP). We also examined systolic VVV of BP using the 
average real variability (ARV), which is calculated as the average of the absolute difference 
in blood pressure between consecutive visits. As such, ARV accounts for the order in which 
the blood pressure measurements were made(ref. 18,19). For example, if a participant had 
six study visits with the following systolic BP measurements (in mm Hg): 120, 140, 185, 
155, 150, 160, the ARV would be calculated as: (|120−140| +|140−185| +|185−155|+|
155−150|+|150−160|)/5 = 22 mm Hg.
Antihypertensive Medication Adherence
For our primary analysis, we used self-reported medication adherence, which was assessed 
at each study visit by asking participants the following yes/no questions: (1) “Have you ever 
had difficulty taking your BP medicine on schedule?” (2) “Have you ever forgotten to take 
your BP medicine?” (3) “Have you ever stopped taking your BP medicine because you felt 
better?” (4) “Have you ever taken less of your BP medicine than the doctor prescribed 
because you felt better?” (5) “Have you ever stopped taking your BP medicine because you 
felt worse?” (6) “Have you ever taken more of your BP medicine than the doctor prescribed 
because you felt your BP was too high?” Participants who responded “no” to all six 
questions were considered to have perfect adherence at the study visit. We calculated the 
proportion of study visits with perfect adherence over the first 12 months of follow-up, 
grouping participants into the following four adherence categories: Perfect (100%); 
Moderately High (75–99%); Moderately Low (50–74%); and Low (<50%).
In a companion analysis, we examined medication adherence by pill count. At each study 
visit, participants were instructed to bring all of their antihypertensive medications to be 
counted by the study coordinators. If a participant took at least 80%, but not more than 
110% of the prescribed medications (or if the BP was controlled without any 
antihypertensive medications), then they were considered adherent at that study visit. We 
calculated the proportion of study visits at which each participant was adherent using the 
same cut-points as described above for self-reported adherence.
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Demographic factors including age, sex, annual income (<$15,000), education (<high school 
degree), whether the participant lived alone, insurance status (Private, Medicare/Medicaid, 
or none), and employment status were determined by self-report. The following 13 comorbid 
conditions were assessed at baseline (current or past): cancer, ischemic heart disease, 
congestive heart failure, left ventricular hypertrophy, arrhythmias or conduction problems, 
cerebrovascular disease, peripheral vascular disease, hepatitis (B or C), cirrhosis, legally 
blind, deaf, shoulder, chest, or left arm pain on exertion lasting over 3 minutes, psychiatric 
problems. Comorbidities were summed and participants were categorized into three groups 
(0, 1 or 2+ comorbidities). The lifestyle measures included any amount of exercise, any 
alcohol use, and current or former smoking history. We also included baseline measured 
GFR category (≥60, 30–59 and 15–29 mL/min per 1.73m2) and baseline proteinuria (> 0.22 
grams/day).
Statistical Analysis
We compared participant baseline characteristics by categories of medication adherence and 
assessed the statistical significance of differences using general linear models or the 
Cochrane-Armitage test for trend, as appropriate. We used multinomial logistic regression to 
examine determinants of medication adherence (moderately high, moderately low, and low, 
each versus perfect adherence). We calculated the mean VVV of BP by adherence category 
and used linear regression to evaluate the association of medication adherence with systolic 
VVV of BP. After conducting unadjusted and age, sex, mean SBP adjusted models, a 
multivariable adjusted model was conducted which included all variables listed in Table 1. 
As all covariates were available for >90% of participants, we conducted complete case 
analyses. This analysis was deemed exempt by the Institutional Review Board at Stanford 
University as all data were de-identified. All analyses were conducted using SAS Enterprise 
Guide 4.3 (Cary, NC).
RESULTS
Of the 1094 participants in the AASK trial cohort, we included 988 in the present analysis 
after applying the inclusion and exclusion criteria. Excluded participants did not 
significantly differ from included participants by age, sex, or comorbid conditions (data not 
shown). However, they did have lower average GFR (44 vs 47 ml/min per 1.73m2, p=0.04) 
and a higher prevalence of proteinuria (49% versus 31%, p<0.001).
Factors Associated with Lower Adherence
Of the 981 participants with information on self-reported adherence, participants with lower 
adherence were generally younger, were more often uninsured, and generally had a higher 
prevalence of comorbid conditions (Table 1). After multivariable adjustment, older age and 
lower eGFR were associated with lower odds of less-than-perfect adherence (Figure 1). 
Females, participants who attended more visits and those randomized to the lower blood 
pressure target group had higher odds of moderately high, moderately low and low 
adherence versus perfect adherence. Results were similar when we examined adherence 
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using pill count (Supplemental Table 1), with the exception that more visits was associated 
with higher odds of perfect adherence (Supplemental Figure 1).
Adherence and Systolic Visit-to Visit Blood Pressure Variability
The average systolic VVV of BP using the coefficient of variation for the overall cohort was 
10.3% (±4.0%), and it increased with progressively lower levels of self-reported adherence 
(Figure 2A). In unadjusted models, participants with low self-reported medication adherence 
had, on average, 2.21% (± 0.33%) higher coefficient of variation compared with participants 
with perfect self-reported adherence (Table 2). Results were attenuated after multivariable 
adjustment for baseline characteristics, but remained statistically significant.
When defined using ARV, the average systolic VVV of BP was 15.2 mm Hg (±6.8 mm Hg), 
and it increased with progressively lower levels of self-reported adherence (Figure 2B). In 
unadjusted models, participants with low self-reported medication adherence had 3.96 mm 
Hg (±0.6 mm Hg) higher ARV on average compared with participants with perfect self-
reported adherence (Table 3). Results were attenuated but remained significant after 
multivariable adjustment. We saw similar patterns of results when adherence was assessed 
using pill counts (Supplemental Figure 2 & Table 2).
DISCUSSION
Using data from the AASK trial, we show that in African Americans with hypertensive 
CKD, lower medication adherence is associated with higher systolic VVV of BP. Our results 
are robust, as they remained statistically significant even after adjusting for differences in 
baseline characteristics and for mean systolic BP. Moreover, our results did not materially 
change when adherence was assessed using self-report or objective pill counts, or when 
VVV of BP was defined as the coefficient of variation or the ARV.
Our findings are consistent with a previous study evaluating the association of 
antihypertensive medication adherence and VVV of BP conducted in a sample of enrollees 
in a Medicare managed care program on at least one antihypertensive medication(ref. 8). In 
that study, low medication adherence was associated with 1.08 mm Hg higher systolic VVV 
of BP (defined as the standard deviation) in fully adjusted models. Our study extends the 
findings of that study to a younger cohort of African American participants with CKD. 
Moreover, that study used only a single non-standard blood pressure measurement at each 
visit while our analysis used the average of the last two of three BP measurements and all 
BP measurements were standardized.
Less than one-third of participants included in our analysis had perfect adherence by self-
report or pill count at all study visits; conversely 20–24% of participants had consistently 
low medication adherence, despite the fact that they were all carefully followed participants 
in a randomized controlled trial. We found that younger participants were more likely to 
have medication non-adherence, confirming findings from a variety of populations, 
including an urban health center in New Orleans(ref. 20), Italian adults with 
hypertension(ref. 21), and older adults in a managed care organization(ref. 22). Alcohol use 
was not associated with medication non-adherence in our analysis, similar to a recent 
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systematic review, which found that only 1 out of 3 studies showed a significant association 
of hypertensive medication adherence with alcohol use(ref. 23). A history of smoking was 
also not associated with adherence in our analysis, consistent with some(ref. 24,25), though 
not all(ref. 26,27), previous studies. Differences in study results likely stem from differences 
in specific definitions used (current, former, ever or never smokers) and differences in 
participant demographics. Notably, we did not find a consistent association of 
socioeconomic factors such as low income, education and lack of insurance with lower 
medication adherence. Taken together, our results highlight the complexities of finding 
consistent identifiers of high-risk populations for medication non-adherence.
Our analysis has several strengths. First, the AASK Trial included a socioeconomically 
diverse participant population with detailed demographic and clinical information. Second, 
we had repeated objective and subjective assessments of medication adherence. Third, we 
were able to use multiple, standardized BP measurements to calculate VVV of BP. However, 
there are also several limitations. First, all participants were enrolled in a clinical trial that 
included randomization to one of two BP targets. Therefore, participants’ BP was closely 
monitored during follow-up, which may have dampened the degree of VVV of BP. However, 
the average VVV of BP in our study is similar to reports in other studies using data from 
other randomized clinical trials(ref. 28,29) and some observational cohorts(ref. 30,31,32). 
Second, participants with diabetes and significant proteinuria were excluded from the study, 
which, coupled with the fact that clinical trial participants are often healthier and more 
adherent than unselected populations, may limit the generalizability of our findings. Finally, 
the instruments we used to assess medication adherence, self-report and pill count, cannot be 
used to confirm whether participants took medications on a day-to-day basis. 
Misclassification of medication adherence could have biased our results towards the null, 
underestimating the true association with VVV of BP.
In summary, our results suggest that in African Americans with hypertensive CKD, lower 
medication adherence is associated with higher systolic VVV of BP. In turn, recent studies 
demonstrate that VVV of BP confers an increased risk for cardiovascular events and 
mortality(ref. 2,3,4,5,6,7). Lower medication adherence has known associations with poor 
outcomes such as cardiovascular hospitalizations and all-cause mortality(ref. 33,34,35), and 
our analysis provides yet another reason to work to improve medication adherence. Whether 
improving medication adherence will reduce VVV of BP and ultimately improve outcomes 
remains to be tested in future studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is known about this topic
• African Americans with hypertensive CKD are at high risk for adverse cardiovascular events, yet 
are often underrepresented in research studies.
• Higher visit-to-visit variability of blood pressure (VVV of BP) is associated with poorer outcomes
• Identification of potentially modifiable risk factors for higher VVV of BP is needed.
What this study adds
• In African Americans with hypertensive kidney disease, participants with lower medication 
adherence were generally younger and had a higher prevalence of comorbid conditions.
• Analyses using self-reported adherence or pill count showed that lower medication adherence is 
associated with higher systolic VVV of BP, defined as the coefficient of variation or as the average 
real variability.
• Results were robust and significant, even after adjusting for differences in baseline characteristics 
and for mean systolic BP.
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Odds ratio of membership in one of the lower adherence groups versus perfect adherence 
group (as measured by self-report) for the specified baseline characteristics. Bars indicate 
95% confidence limits. Models included all baseline characteristics shown, plus income 
group, lives alone, employed, number of comorbidities, body mass index, exercise, alcohol 
use, smoking, and randomized drug type.
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Mean systolic visit-to-visit variability of blood pressure by medication adherence category 
assessed by self-report. Systolic visit-to-visit variability of blood pressure defined as A) 
coefficient of variation and B) average real variability. Values indicate mean and error bars 
indicate one standard deviation.
*p-value <0.001 (versus perfect adherence).
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